357 related articles for article (PubMed ID: 17043122)
1. Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
Schwarz P; Janbon G; Dromer F; Lortholary O; Dannaoui E
Antimicrob Agents Chemother; 2007 Jan; 51(1):383-5. PubMed ID: 17043122
[TBL] [Abstract][Full Text] [Related]
2. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs.
Tay ST; Tanty Haryanty T; Ng KP; Rohani MY; Hamimah H
Mycoses; 2006 Jul; 49(4):324-30. PubMed ID: 16784448
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis.
Schwarz P; Dromer F; Lortholary O; Dannaoui E
Antimicrob Agents Chemother; 2006 Jan; 50(1):113-20. PubMed ID: 16377675
[TBL] [Abstract][Full Text] [Related]
4. Antifungal drug combinations for Cryptococcus neoformans and Prototheca spp.
Srimuang S; Prariyachatigul C; Chaiprasert A; Rungsipanuratn W; Tanphaichitra D
J Med Assoc Thai; 2000 Jan; 83(1):57-60. PubMed ID: 10710870
[TBL] [Abstract][Full Text] [Related]
5. In vitro susceptibility of Cryptococcus neoformans isolates from patients with acquired immunodeficiency syndrome.
Poon M; Cronin DC; Wormser GP; Bottone EJ
Arch Pathol Lab Med; 1988 Feb; 112(2):161-2. PubMed ID: 3276290
[TBL] [Abstract][Full Text] [Related]
6. Antifungal susceptibility of Cryptococcus neoformans to amphotericin B and fluconazole.
Khyriem AB; Sujatha S; Parija SC
Indian J Pathol Microbiol; 2006 Apr; 49(2):307-8. PubMed ID: 16933750
[TBL] [Abstract][Full Text] [Related]
7. In vitro interaction of flucytosine with conventional and new antifungals against Cryptococcus neoformans clinical isolates.
Schwarz P; Dromer F; Lortholary O; Dannaoui E
Antimicrob Agents Chemother; 2003 Oct; 47(10):3361-4. PubMed ID: 14506059
[TBL] [Abstract][Full Text] [Related]
8. In vitro susceptibility of Cryptococcus gattii clinical isolates.
Gomez-Lopez A; Zaragoza O; Dos Anjos Martins M; Melhem MC; Rodriguez-Tudela JL; Cuenca-Estrella M
Clin Microbiol Infect; 2008 Jul; 14(7):727-30. PubMed ID: 18558948
[TBL] [Abstract][Full Text] [Related]
9. 5-Fluorocytosine resistance in clinical isolates of Cryptococcus neoformans.
Chin CS; Cheong YM; Wong YH
Med J Malaysia; 1989 Sep; 44(3):194-8. PubMed ID: 2696871
[TBL] [Abstract][Full Text] [Related]
10. Adaptation to Fluconazole via Aneuploidy Enables Cross-Adaptation to Amphotericin B and Flucytosine in Cryptococcus neoformans.
Yang F; Gritsenko V; Lu H; Zhen C; Gao L; Berman J; Jiang YY
Microbiol Spectr; 2021 Oct; 9(2):e0072321. PubMed ID: 34585947
[TBL] [Abstract][Full Text] [Related]
11. Enhanced diallyl trisulfide has in vitro synergy with amphotericin B against Cryptococcus neoformans.
Shen J; Davis LE; Wallace JM; Cai Y; Lawson LD
Planta Med; 1996 Oct; 62(5):415-8. PubMed ID: 8923805
[TBL] [Abstract][Full Text] [Related]
12. Molecular typing and in vitro resistance of Cryptococcus neoformans clinical isolates obtained in Germany between 2011 and 2017.
Selb R; Fuchs V; Graf B; Hamprecht A; Hogardt M; Sedlacek L; Schwarz R; Idelevich EA; Becker SL; Held J; Küpper-Tetzel CP; McCormick-Smith I; Heckmann D; Gerkrath J; Han CO; Wilmes D; Rickerts V
Int J Med Microbiol; 2019 Sep; 309(6):151336. PubMed ID: 31444102
[TBL] [Abstract][Full Text] [Related]
13. Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates: April 2000 to March 2002.
Sar B; Monchy D; Vann M; Keo C; Sarthou JL; Buisson Y
J Antimicrob Chemother; 2004 Aug; 54(2):563-5. PubMed ID: 15254027
[TBL] [Abstract][Full Text] [Related]
14. Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans.
Perkins A; Gomez-Lopez A; Mellado E; Rodriguez-Tudela JL; Cuenca-Estrella M
J Antimicrob Chemother; 2005 Dec; 56(6):1144-7. PubMed ID: 16282208
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo studies on synergistic antifungal activity.
Shadomy S
Contrib Microbiol Immunol; 1977; 4():147-57. PubMed ID: 342191
[No Abstract] [Full Text] [Related]
16. In vitro susceptibility of Cryptococcus neoformans clinical isolates from Egypt to seven antifungal drugs.
Abdel-Salam HA
Mycoses; 2005 Sep; 48(5):327-32. PubMed ID: 16115103
[TBL] [Abstract][Full Text] [Related]
17. Amphotericin B resistant isolates of Cryptococcus neoformans without alteration in sterol biosynthesis.
Joseph-Horne T; Loeffler RS; Hollomon DW; Kelly SL
J Med Vet Mycol; 1996; 34(3):223-5. PubMed ID: 8803806
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of amphotericin B and flucytosine in combination against Candida albicans and Cryptococcus neoformans using time-kill methodology.
Keele DJ; DeLallo VC; Lewis RE; Ernst EJ; Klepser ME
Diagn Microbiol Infect Dis; 2001 Nov; 41(3):121-6. PubMed ID: 11750164
[TBL] [Abstract][Full Text] [Related]
19. In vitro synergism of concentrated Allium sativum extract and amphotericin B against Cryptococcus neoformans.
Davis LE; Shen J; Royer RE
Planta Med; 1994 Dec; 60(6):546-9. PubMed ID: 7809209
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanism of flucytosine resistance in Candida lusitaniae: contribution of the FCY2, FCY1, and FUR1 genes to 5-fluorouracil and fluconazole cross-resistance.
Papon N; Noël T; Florent M; Gibot-Leclerc S; Jean D; Chastin C; Villard J; Chapeland-Leclerc F
Antimicrob Agents Chemother; 2007 Jan; 51(1):369-71. PubMed ID: 17060521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
